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Protocol
AbstrAct
Introduction While some evidence exists that real-
time remote symptom monitoring devices can decrease 
morbidity and prevent unplanned admissions in 
oncology patients, overall, these studies have significant 
methodological weaknesses. The electronic Symptom 
Management using the Advanced Symptom Management 
System (ASyMS) Remote Technology (eSMART) study is 
designed to specifically address these weaknesses with an 
appropriately powered, repeated-measures, parallel-group 
stratified randomised controlled trial of oncology patients.
Methods and analysis A total of 1108 patients scheduled 
to commence first-line chemotherapy (CTX) for breast, 
colorectal or haematological cancer will be recruited from 
multiple sites across five European countries. Patients 
will be randomised (1:1) to the ASyMS intervention 
(intervention group) or to standard care currently available 
at each site (control group). Patients in the control and 
intervention groups will complete a demographic and 
clinical questionnaire, as well as a set of valid and 
reliable electronic patient-reported outcome measures 
at enrolment, after each of their CTX cycles (up to a 
maximum of six cycles) and at 3, 6, 9 and 12 months after 
completion of their sixth cycle of CTX. Outcomes that will 
be assessed include symptom burden (primary outcome), 
quality of life, supportive care needs, anxiety, self-care 
self-efficacy, work limitations and cost effectiveness and, 
from a health professional perspective, changes in clinical 
practice (secondary outcomes).
Ethics and dissemination Ethical approval will be 
obtained prior to the implementation of all major study 
amendments. Applications will be submitted to all of the 
ethics committees that granted initial approval. eSMART 
received approval from the relevant ethics committees 
at all of the clinical sites across the five participating 
countries. In collaboration with the European Cancer 
Patient Coalition (ECPC), the trial results will be 
disseminated through publications in scientific journals, 
presentations at international conferences, and postings 
on the eSMART website and other relevant clinician and 
consumer websites; establishment of an eSMART website 
(www. esmartproject. eu) with publicly accessible general 
information; creation of an eSMART Twitter Handle, and 
production of a toolkit for implementing/utilising the 
ASyMS technology in a variety of clinical practices and 
other transferable health care contexts.
Trial registration number NCT02356081.
InTroducTIon
Recent advances in chemotherapy (CTX) 
have resulted in considerable increases in 
overall cancer survival rates.1–4 However, 
this treatment is associated with signifi-
cant5 6 and occasionally life-threatening 
side effects.7–9 In addition, CTX-related 
symptoms can lead to poor treatment adher-
ence,10 increased hospitalisations,7–9 11 12 
increased costs7–9 11 12 and impaired quality 
Strengths and limitations of this study
 ► Suitably powered multicentre (multiple clinical 
sites across five European countries) randomised 
controlled trial of the efficacy of remote technology 
to manage symptoms in oncology patients.
 ► Measurement of patient outcomes during active 
treatment through to and inclusive of a survivorship 
period (ie, 1 year post treatment).
 ► Potential bias associated with the possibility that 
only technologically confident patients will agree 
to take part and the limited number of European 
countries involved in the study.
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of life (QoL).13–15 CTX-related symptoms occur not only 
during active treatment but can persist into survivor-
ship.6 16 17
While symptom assessment is an essential component 
of cancer care, regular and systematic approaches to 
symptom assessment are lacking.18 19 Currently, identi-
fication of CTX-related symptoms primarily relies on 
retrospective patient recall, which, apart from being 
prone to recall bias and inaccuracy,20 may be of limited 
benefit because delays in reports of clinically signifi-
cant and potentially life-threatening symptoms impair 
effective symptom management.21 Ineffective symptom 
management results in disruptions to health-related 
QoL (HR-QoL) and increases supportive care needs.22 
These unfavourable outcomes have negative effects on 
patients and their family caregivers.23 Effective symptom 
assessment and management is further compounded by 
the transition of cancer services from traditional inpa-
tient care towards care delivered within local settings.24 
This shift in care delivery means that many patients are 
required to engage in self-care activities to prevent or 
reduce the severity of CTX-related symptoms24 and make 
important treatment decisions without their clinicians.25 
The use of innovative technological systems provides an 
affordable solution to the increasing demands placed on 
acute care through the delivery of care in the home and 
rural settings.26 27 Such remote monitoring systems facili-
tate real-time communication between patients and their 
clinicians26 and in recent years there has been a rapid 
increase in the number of these systems being used in 
the cancer setting,28 many of which require further devel-
opment in order to enhance their usability and clinical 
integration.
One of the more advanced remote monitoring systems 
available to assess and manage CTX toxicities is the 
Advanced Symptom Management System (ASyMS), 
which was developed by researchers, cancer clinicians 
and people with cancer.29–36 ASyMS is a mobile phone-
based remote monitoring system that enables the 
‘real-time’ monitoring of patients’ symptoms through use 
of patient-reported outcome measures (PROMs). The 
use of PROMs is advocated as an effective way to identify 
aspects of a patient’s health status,37 enhance manage-
ment of CTX-related symptoms, alleviate patient anxiety 
and promote self-care self-efficacy.38 Combined with 
technology-driven interventions that are able to capture 
symptom data in real time, electronic PROMs (ePROMs) 
allow for rapid clinical decision-making and interventions 
to improve patient outcomes.39 In addition, they enable 
the delivery of quality care irrespective of distance27 and 
economic or cultural contexts.
Complementary to such technological innovations is 
the advent of predictive risk models (PRMs) which enable 
care to be effectively triaged and clinicians to employ a 
preventative and anticipatory model of care through 
identification of patients at greatest risk for CTX-re-
lated symptoms.40 Collectively, the use of technologically 
driven, real-time symptom monitoring and predictive risk 
modelling will allow for timely, high-quality, person-cen-
tred supportive care.
Recent evidence demonstrates that remote symptom 
monitoring through patient report leads to clear clin-
ical benefits.41 The clinical impact of these interventions 
includes decreased morbidity, improved HR-QoL and a 
reduction in hospital admissions in oncology patients.41 
However, the concept is still relatively novel with very 
few studies conducted in cancer settings.42 Methodolog-
ical weaknesses have been identified and none included 
a health economic analysis.42 The electronic Symptom 
Management using the Advanced Symptom Manage-
ment System Remote Technology (eSMART) study is 
designed to address these issues with an appropriately 
powered, randomised controlled trial (RCT) which will 
demonstrate the effects of the ASyMS intervention on 
key patient outcomes and delivery of care provided to 
oncology patients during and after CTX.
MeThods and analysIs 
eSMART is a two-part, pragmatic, 5-year RCT being 
conducted in multiple sites across five countries (ie, 
Austria, Greece, Ireland, Norway and the UK). Part 2, 
the protocol that is described in this paper, is the RCT. 
Part 1 was concerned with the necessary preparatory work 
required for the RCT (including scoping review, clinical 
algorithm refinement, patient/clinical advisory group 
discussions, translation and linguistic validation of all 
study materials and feasibility testing of the ASyMS tech-
nology). The eSMART study is sponsored and led by the 
University of Surrey in the UK and is registered on  Clini-
calTrials. gov (NCT02356081).
The primary aim of eSMART is to evaluate the short-
term and long-term impact of the ASyMS technology on 
patient-reported outcomes in oncology patients receiving 
first-line CTX for breast cancer, colorectal cancer (CRC) 
and haematological (ie, Hodgkin’s disease (HD), 
non-Hodgkin's lymphoma (NHL)) cancer. In addition, 
eSMART will evaluate the cost-effectiveness of the ASyMS 
technology, as well as changes in clinical practice that may 
follow its full deployment in different European health-
care settings. The primary and secondary study objectives 
and their associated outcome measures (ePROMs) are as 
follows.
Primary objective
To determine whether, compared with standard care, the 
ASyMS intervention can lead to reduced symptom burden 
during active CTX for breast cancer, CRC, HD or NHL as 
evidenced by a statistically significantly lower total Memo-
rial Symptom Assessment Scale (MSAS)43 score over six 
CTX cycles. The MSAS is a valid and reliable PROM43 
that evaluates 32 physical and psychological symptoms 
according to their frequency, severity and distress/bother 
to the patient in the past week.
secondary objectives
To determine whether, compared with standard care, the 
ASyMS intervention can lead to the following outcomes 
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in patients receiving CTX for breast cancer, CRC, HD or 
NHL:
1. Reduced symptom burden during active CTX as 
evidenced by statistically significantly lower total 
MSAS scores at prespecified time points and at 
1 year following the intervention.
2. Reduced symptom burden at mid-CTX cycle 
time point (ie, at a time point when symptom 
burden is known to reach its peak), as evidenced by 
a statistically significantly lower total MSAS score.
3. Increased HR-QoL (ie, statistically significantly 
higher scores on overall and HR-QoL domains 
of the Functional Assessment of Cancer Therapy-
General44 during active CTX and/or at the 1 year 
follow-up.
4. Reduced supportive care needs (ie, statistically 
significantly lower scores on supportive care needs 
domains of the Supportive Care Needs Survey-
Short Form 3445 during active CTX and/or at the 
1 year follow-up.
5. Reduced anxiety (ie, statistically significantly lower 
scores on the state and/or trait anxiety domains of 
the State-Trait Anxiety Inventory-Revised46 during 
active CTX and/or at the 1 year follow-up.
6. Improved self-care self-efficacy (ie, statistically 
significantly higher self-efficacy scores on the 
Communication and Attitudinal Self-Efficacy scale 
for cancer47 during active CTX and/or at the 1 year 
follow-up.
7. Fewer work limitations (ie, statistically significantly 
lower work limitations scores on the Work 
Limitations Questionnaire 48 during active CTX 
and/or at the 1 year follow-up.
In addition, the following outcomes will be evaluated:
1. The cost-effectiveness of the ASyMS intervention 
for the management of CTX-related symptoms 
by combining resource use data with quality-
adjusted life-years measured with the EuroQol 
5-Dimensions49 and use of the Client Services 
Receipt Inventory.50
2. Changes in clinical practice as a result of the ASyMS 
intervention by promoting an anticipatory and 
preventative model of care that enables more care 
to be delivered in local settings.
3. PRMs to predict CTX-related symptoms in patients 
with breast cancer, CRC, HD or NHL by combining 
demographic, clinical, social and health service 
data collected from previous studies, as well as the 
current study, to inform the predictions made. 
This component will move beyond traditional 
approaches to manage symptoms in oncology 
patients receiving CTX to more tailored and 
anticipatory approaches.
setting
Patients (n=1108) will be recruited from multiple sites 
across five European countries (see online supplemen-
tary appendix 1 for details).
Patient screening and recruitment
At each site, eligible patients (see Box 1 for eligibility 
criteria) will be identified by the local site Principal 
Investigator or other members of the local clinical team. 
Patients will be recruited from outpatient and/or inpa-
tient oncology settings prior to the initiation of CTX.
Patient recruitment
Clinical staff at each site and/or dedicated research staff 
will assist with the recruitment of patients. Patients will be 
given a sufficient period of time to consider participation 
and they will be advised that they can discuss the study 
with any significant others and/or health professionals 
prior to making a final decision. If patients agree to partic-
ipate, they will be asked to attend the clinic prior to their 
pre arranged appointment for CTX (enrolment visit). 
During the enrolment visit, written informed consent will 
be obtained (see online supplementary appendix 2).
randomisation
Following the consent procedure, randomisation will be 
performed remotely and independently by the Surrey 
Clinical Trials Unit (CTU) using the Promasys system 
(OmniComm Systems). Research staff at each site will 
log into the randomisation site. Eligible patients will be 
Box 1 Eligibility criteria
Patients will be included in the RCT if they are
 ► Adults (≥18 years)
 ► Diagnosed with breast cancer, CRC, HD or NHL
 ► Scheduled to receive first-line CTX or (if previous CTX has been 
received) scheduled to receive CTX for the first time in the last five 
years
 ► Scheduled to receive 2-weekly, 3-weekly or 4-weekly CTX protocols 
(ie, CTX administered every 14, 21 or 28 days, respectively)
 ► Scheduled to receive a minimum of three cycles of CTX
 ► Physically/psychologically fit to participate in the study
 ► Able to understand and communicate in the respective language
Patients will be excluded from the RCT if they are
 ► Diagnosed with a distant metastasis in the case of breast cancer 
or CRC
 ► Experiencing B symptoms in the context of an HD or NHL diagnosis
 ► Scheduled to receive concurrent radiotherapy
 ► Scheduled to receive weekly CTX
 ► Diagnosed with recurrent cancer or another type of cancer within 
5 years prior to recruitment (with the exception of non-melanoma 
skin cancer)
 ► Patients who have CTX within the previous five years for any medical 
reason
 ► Unable to provide written informed consent
CRC, colorectal cancer; CTX, chemotherapy; HD, Hodgkin’s disease; NHL, 
non-Hodgkin's lymphoma; RCT, randomised controlled trial.
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randomised via a web-based electronic case report form 
and will be stratified by site and type of cancer. These 
steps will ensure that bias in treatment assignment, 
specifically selection bias, allocation concealment bias 
and confounding bias, will be eliminated. This alloca-
tion will determine whether the patient is allocated to 
the mid-CTX measurement (30% of total study sample). 
Information concerning patient eligibility, patient unique 
ID number, date of randomisation, allocation group 
and written informed consent will be recorded in the 
Promasys system. Due to the nature of the intervention, 
blinding is not possible. However, to mitigate the adverse 
effects of blinding bias, patient information sheets (see 
online supplementary appendix 3) will be deliberately 
produced to avoid any reference to ‘intervention group’ 
or ‘control group’ as this information could discourage 
patients allocated to the control group from taking part. 
Instead, all patients will be informed that they will be 
randomly allocated to one of two different methods of 
symptom management during CTX (ie, either ‘mobile 
phone group’ or ‘normal care group’). In addition, 
patients will be blinded to study hypotheses.
Prior to advising patients about the outcome of the 
randomisation process, all patients will be asked to 
complete a set of ePROMs on a tablet personal computer 
(PC) or desktop PC. If patients are allocated to the inter-
vention group, the research staff will provide a brief 
overview of study procedures and train the patient to use 
the ASyMS technology prior to commencement of CTX. 
If patients are allocated to the control group, the research 
staff will provide a brief overview of study procedures.
Intervention
The ASyMS intervention uses mobile phone technology 
to enable real-time monitoring of patients’ CTX-related 
symptoms (figure 1A). The core component of the ASyMS 
intervention is the mobile phone device (ie, ASyMS 
patient handset shown in figure 1B), which contains an 
electronic version of the ASyMS symptom questionnaire 
(CTX Toxicity Self-Assessment Questionnaire (CTAQ)). 
The CTAQ assesses 10 CTX-related symptoms (ie, feeling 
sick, being sick, diarrhoea, constipation, sore mouth and/
or throat, paraesthesias, sore hands and/or feet, flu-like 
symptoms/infection, tiredness, pain). An additional item 
is included to give the patient the option to report up to 
six further symptoms.
This ePROM evaluates three dimensions of CTX-re-
lated toxicity on separate response scales, namely 
incidence, severity and bother. Symptom occurrence is 
reported on a dichotomous scale (ie, yes/no). When the 
answer is ‘yes’, the patient is asked to rate the severity 
and bother of each symptom. A three-point scale (mild, 
moderate, severe) is used to evaluate symptom severity. 
The severity indicators have associated descriptors based 
Figure 1 Electronic Symptom Management using the Advanced Symptom Management System Remote Technology 
(eSMART) intervention: (A) Diagram illustrating the eSMART model of care. (B) Patient ASyMS device. Example of the 
home screen where the patient can access self-care advice, their daily symptom questionnaire and any text messages sent by 
clinician. (C) Clinician alert-handling process. These screenshots provide an example of the type of information available on the 
clinician handset, that is, severity of alert, patient ID and list of reported symptoms.
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on the Common Terminology Criteria for Adverse Events 
V.4.0.51 Mild symptoms are defined using CTC 1 criteria, 
moderate symptoms CTC 2 and severe symptoms CTC 3. 
This approach ensures that ratings of symptom severity 
are easily translated into routine practice and incorpo-
rated into current management guidelines. A four-point 
scale (not at all, a little, quite a bit, very much) evaluates 
how much a patient is bothered by the symptom. All 
symptoms will be rated using a recall period of the past 
24 hours. The CTAQ symptom questionnaire was used in 
previous ASyMS studies.33 The validity and reliability of 
this tool was demonstrated in oncology patients receiving 
CTX.33
Prior to completing the ePROM, patients will be asked 
to indicate whether they are at home or in hospital, 
they will complete the CTAQ symptom questionnaire 
on the ASyMS patient handset and take their tempera-
ture with a tympanic electronic thermometer. Patients 
will enter this value into the handset once daily and at 
any time they feel unwell after each of their CTX cycles 
(up to a maximum of six cycles). Patients involved 
in previous ASyMS studies did not find this process 
burdensome and adherence across patient populations 
was high.36 52Patients will immediately receive auto-
mated, evidence-based self-care advice based on their 
symptom reports. In addition, the ASyMS patient hand-
sets will provide access to a self-care library, symptom 
graphs (detailing trends in individual symptoms experi-
enced) and contact numbers for care teams and patient 
support organisations in their country.
The patients’ ‘real-time’ symptom information will 
be sent automatically via a secured connection to Doco-
bo’s (software provider) secure server. Patients will be 
advised via the ASyMS patient handset if their symptom 
data were sent successfully to the server. If the patient 
is at home and the incoming symptom reports are of 
clinical concern (eg, a developing infection), the server 
software will generate alerts that will be sent to the 
patients’ clinician. Two levels of alerts will be generated 
if symptoms require intervention. The first of these, an 
amber alert (to be addressed within 8 hours), will be for 
symptoms that are bordering on becoming problem-
atic and would be responsive to early interventions. In 
such cases, clinicians will make a clinical judgement as 
to whether or not to call the patient following a review 
of the patient’s symptom information on the ASyMS 
website (ie, the patient’s ‘real-time’ symptom reports, 
patient symptom graphs and the 28-day-view patient 
display). A red alert (to be addressed within 30 min) will 
be triggered for symptoms that are severe or life-threat-
ening (eg, fever). These time frames, within which an 
alert is to be answered, are designed to facilitate timely 
clinical intervention while also being manageable for 
the clinicians.
Clinicians will receive alerts on a dedicated ASyMS 
clinician handset (ie, a specialised mobile phone that 
the clinician responsible for handling alerts on a given 
shift (‘alert handler’) will carry with them at all times). 
All clinical sites will be provided with centrally gener-
ated, site-specific usernames and passwords that will 
allow clinicians access to the ASyMS web-based system. 
When an alert is triggered, the ASyMS clinician handset 
will play an audio attention prompt in the form of a 
repetitive, high-pitched ringing. Alert handlers will be 
able to identify which patient triggered the alert by 
tapping the relevant alert icon on the ASyMS clinician 
handset to reveal the type of incoming alert (amber or 
red), the patient study ID number, the time elapsed 
since the alert was received and, when available, a list of 
symptoms that triggered the specific alert (figure 1C). 
This information will allow the alert handler to match 
the alert to the patient on the secure eSMART website, 
where all patients’ symptom reports, demographic and 
clinical information, contact telephone numbers and 
addresses are viewable. On receipt of an alert, the clini-
cian will view the patient’s ‘real-time’ symptom reports 
on a secure web page, before contacting the patient to 
initiate the appropriate intervention. Information on 
this secure website will include demographic and clin-
ical information to allow clinicians to verify the patient’s 
identity and to assist in decision-making and subsequent 
interventions. Clinicians can use information stored 
on the eSMART website to conduct a clinical assess-
ment with the patient. The alert handler will provide 
appropriate, standardised interventions using clinical 
algorithms which are based on international, national 
and local guidelines, and feedback from clinicians and 
patients. The alert handler will then document the 
actions/interventions performed, and sign off the alert 
on the eSMART website.
In addition to patient information being stored on the 
website for access during alert handling, a hard copy of 
the patient’s study ID number, name and contact details 
will be kept in a locked file at each site in case the eSMART 
server malfunctions or is unavailable. Thus, alert handlers 
will be able to contact the patient to assess their symptoms 
and intervene.
TraInIng/educaTIon
Patient training (intervention group)
Patients allocated to the intervention group will 
be provided with the ASyMS patient handset and a 
tympanic thermometer. The research staff will instruct 
the patients on how to use the handset. If a patient 
experiences any problems with this procedure, addi-
tional training will be done until the patient feels 
comfortable using the ASyMS patient handset and they 
can successfully transmit their symptom information to 
the server. A manual for the handset containing instruc-
tions and contact numbers will be given to each patient. 
In the interest of patient safety, patients who will use 
the ASyMS intervention will be reminded that in cases 
where the technology fails, standard care will apply. For 
example, if symptoms are reported that will trigger an 
alert, before closing the questionnaire the patient will 
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receive a message to inform them that their symptoms 
will be reviewed by a clinician and that they may receive 
a call within the time frame given. If patients do not 
receive any contact from the hospital (ie, in the case 
of technology failure) and feel that their symptoms are 
of concern, they are always advised at the outset of the 
study to use the standard care procedures.
Patients will be advised that they can still use their 
ASyMS handset if they are hospitalised. In this instance, 
no alerts will be triggered but patient data will be trans-
ferred to the server if internet connectivity is available. 
Patients in the intervention group will be informed about 
data collection procedures.
Patient training (control group)
Patients allocated to the control group will be informed 
about data collection procedures (see ‘Data collection 
and management’ section).
clinician training on the intervention
Dedicated training sessions with members of each clin-
ical team (local ‘alert handlers’) will take place prior to 
commencement of patient recruitment. In the interest 
of patient safety, clinicians will be reminded that in 
cases where the technology fails standard care will apply 
for patients in the intervention group throughout their 
participation in the study.
data collection and management
Research design: Repeated measures, parallel group, 
stratified RCT.
Demographic and clinical data will be collected at the 
outset of the study. The outcome measures used in this 
study were selected following a review of the literature 
as advocated by the Medical Research Council frame-
work for complex interventions.53–55 These PROMs 
were selected as the best available and most appropriate 
measures to address the primary and secondary objectives 
listed above.
active treatment period
Irrespective of study condition, all patients will be asked 
to complete a set of ePROMs (primary and secondary) at 
enrolment (ie, prior to first CTX) and around the start of 
each subsequent CTX (between 2 days before and 1 day 
after CTX administration) up to a maximum of six cycles 
of CTX. In addition, a subsample (30%) of randomly 
selected patients from the intervention and control 
groups will be asked to complete a mid- cycle measure-
ment (mid-CTX) of the primary outcome measure (ie, 
MSAS) at each cycle in order to capture additional data on 
symptom burden at this time. Depending on the duration 
of a given CTX cycle and patient availability, patients will 
be asked to complete the mid -CTX assessment between 
days 6 and 8 for 2- weekly protocols, between days 9 and 
11 for 3 -weekly protocols and between days 13 and 15 for 
4- weekly protocols.
PROM data will be collected in the hospital, where 
patients will be asked to use a tablet PC or desktop PC 
each time they are required to complete the question-
naires. When required, research staff will assist patients 
to enter information on the tablet PC/PC. The tablet 
PC/PC will hold electronic versions of the PROMs ques-
tionnaires, allowing data to be transferred to the secure 
server. During active CTX, the data collection will coin-
cide with patients’ visits for their next CTX cycle. To offer 
patients more flexibility, they may also have the option 
of completing PROM data via a secure web link sent to 
the patient’s email. Data collection of PROMs will take 
approximately 40–60 min; patients will be encouraged to 
take a break at any stage and will be regularly informed 
of their progress through the questionnaires. Should 
patients decide to take a break, the tablet PC/PC will 
automatically resume where they discontinued.
The data collection from the subset of patients who 
complete the mid -cycle MSAS measurements will be 
conducted by using either a secure web link for those 
patients who use email or through a telephone interview 
with the research staff. During this mid-cycle measure-
ment, the research staff will record patient responses to 
the MSAS items on the same tablet PC/PC that will be 
used for patient self -reported data collection.
Follow -up period
On completion of a maximum of six cycles of CTX, both 
the intervention and control groups will be followed 
for 1 year to evaluate sustainability of the intervention 
effects. Follow-up data will be collected at pre specified 
time points every three months. A post- CTX ‘baseline 
assessment’ will take place after the end of the final CTX 
cycle. Subsequent assessments will take place at 3, 6, 9 and 
12 months following this ‘baseline assessment’.
In order to reliably assess the sustained effects of the 
intervention, it is important that strategies are put in 
place to minimise the risk of attrition during the follow-up 
period. Therefore, a sequential mixed -mode design for 
data collection will be used to allow for flexibility in data 
collection and to control for non- respondent follow- up. 
PROM data will be collected in the hospital, where patients 
will be asked to use a tablet PC or PC each time they are 
required to complete the ePROMs. Patients will be given 
two alternative options if data cannot be collected in 
clinics using the tablet PC/PC: (1) internet surveys (sent 
via personalised emails) with automated reminders sent 
at 14 and 21 days post-due date to non-responders or (2) 
telephone-conducted interviews completed by research 
staff, who will enter data on a tablet PC/PC.
The use of sequential mixed-mode design for non-re-
spondent follow-up may enhance perceptions of the 
importance of the research, increase response rates, be 
cost effective and reduce non-response bias with minimal 
effect on data quality.56
sample size calculation
Sample size estimation was based on existing evidence 
of differences in total MSAS scores between interven-
tion group and control group (ie, a difference between 
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intervention and control groups of 1.45 – 1.30=0.15).57 
Drawing on these data, a sample size estimation analysis 
indicated that for a difference in total MSAS score of 0.15 
(SD=0.6) given an effect size of 0.25, with four repeated 
measures after enrolment and one enrolment measure, 
a sample of 776 patients (110 patients with haemato-
logical cancers and 333 patients with breast cancer and 
CRC) will provide 90% power for a two-sided 5% signif-
icance level.58 Allowing for an attrition rate of 30%, a 
total of 1108 patients will need to be recruited. During 
the postintervention follow-up period, it is assumed 
that an additional 30% of patients will dropout, giving a 
sample of 544 expected to complete the study 12 months 
post treatment.
In addition, to allow for a mid-CTX comparison of 
MSAS scores between intervention and control groups, 
a random 30% of the total sample recruited for the RCT 
(ie, n=334 (n=122 patients with CRC (61 intervention/61 
control), n=122 patients with breast cancer (61 interven-
tion/61 control) and n=90 patients with haematological 
cancer (45 intervention/45 control)) will be selected to 
provide data at this time point.
data analysis plan
The statistical analysis of the data will be the responsi-
bility of the Surrey CTU in conjunction with University 
of Dundee (please see the complete data analysis plan in 
online supplementary appendix 4). Demographic and 
clinical characteristics recorded at enrolment will be 
tabulated by treatment groups. Descriptive statistics will 
include n, mean, SD, median, minimum and maximum. 
All analyses will follow the guidance contained in the ICH 
E9 ‘Statistical Principles for Clinical Trials’ (http://www. 
emea. europa. eu/ docs/ en_ GB/ document_ library/ Scien-
tific_ guideline/ 2009/ 09/ WC500002928. pdf). Analysis 
of these RCT data will be based on the intention-to-treat 
principle.
Treatment phase
Study outcomes will be described as means and SD. 
Transformations may be required when the distribu-
tions are non-normal. Enrolment characteristics will 
be described for the whole trial and separately by type 
of cancer. The primary outcome of MSAS total score is 
continuous and will be assessed in a repeated-measures 
analysis using mixed models. Hence, the analysis will test 
the difference between ASyMS and standard care groups 
in the change in symptoms between enrolment and 
repeated follow-up. The primary hypothesis will be tested 
through the regression parameter for the ASyMS versus 
standard care groups, adjusting for enrolment MSAS as 
well as stratified by type of cancer and country. Adjust-
ments will be made for length of treatment, age, gender, 
as well as symptom prevalence and severity at enrolment. 
The prespecified subgroup analyses by type of cancer, 
country, age, gender and symptom prevalence and 
severity will be assessed by fitting trial arm by subgroup 
interaction parameters.
Should the active recruitment period of the RCT over 
run, it is acknowledged that this may affect the number of 
patients with data at all time points at the designated end of 
the follow-up. During the follow-up period, a separate anal-
ysis will be performed to indicate how many patients would 
be required by the end of the follow-up period.
Follow-up phase
Two mixed-models analyses will be carried out. First, the 
repeated measures of outcomes in the extended follow-up 
will be added to those already obtained from the active 
CTX period. This analysis will be a longer-term follow-up 
of the active CTX period and has the advantage of further 
repeated measures adding power to the comparison. It 
will test whether any effect seen after the trial is sustained 
for up to a year. Post-CTX management is highly individ-
ualised. Therefore, groups of patients are expected to 
receive different maintenance treatment based on cancer 
diagnosis and disease characteristics and different models 
of follow-up (eg, traditional, open access, risk stratified). 
Therefore, additional subgroup analyses will be performed 
and adjustments made for these differing characteristics in 
the modelling.
Second, a separate analysis will take baseline as the end 
of intervention and analyse the repeated measures of the 
outcomes up to 12 months. This analysis will be an obser-
vational cohort analysis of the postintervention stage and 
will require that more confounding factors be taken into 
account. The analyses will use mixed models as in the active 
intervention period. The extent of missing data in the 
outcomes will be explored and the reasons for missing data 
noted.
Monitoring
The Surrey CTU has developed a monitoring plan that 
will record all of the information regarding monitoring. 
Each clinical site will be responsible for performing their 
monitoring. In addition, a Data Monitoring Committee 
(DMC) was established. The role of the DMC is to review 
accumulating study data related to the safety and efficacy 
of the study intervention and to ensure continued scientific 
validity and merit of the study.
safety reporting
Any study-related incidents will be reported to the 
national competent authority in each country. The local 
ethics committee that granted ethical approval in each 
country will be informed.
Trial status
The RCT is now open and actively recruiting patients.
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